Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dov Nitzan is active.

Publication


Featured researches published by Dov Nitzan.


Bioorganic & Medicinal Chemistry Letters | 2010

Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors.

Hanbiao Yang; Robert Than Hendricks; Nidhi Arora; Dov Nitzan; Calvin Yee; Matthew C. Lucas; Yanli Yang; Amy Fung; Sonal Rajyaguru; Seth F. Harris; Vincent Leveque; Julie Q. Hang; Sophie Le Pogam; Deborah Carol Reuter; Gisele Tavares

Conformational modeling has been successfully applied to the design of cyclic bioisosteres used to replace a conformationally rigid amide bond in a series of thiophene carboxylate inhibitors of HCV NS5B polymerase. Select compounds were equipotent with the original amide series. Single-point mutant binding studies, in combination with inhibition structure-activity relationships, suggest this new series interacts at the Thumb-II domain of NS5B. Inhibitor binding at the Thumb-II site was ultimately confirmed by solving a crystal structure of 8b complexed with NS5B.


Drug Metabolism and Disposition | 2004

IDENTIFICATION OF GLUTATHIONE-DERIVED METABOLITES FROM AN IP RECEPTOR ANTAGONIST

William L. Fitch; Pamela W. Berry; Ya-Ping Tu; Ali Tabatabaei; Lee Edwin Lowrie; Francisco Javier Lopez-Tapia; Yanzhou Liu; Dov Nitzan; Mohammad R. Masjedizadeh; Aravamuthan Varadarajan

The metabolic fate of three aromatic carboxylic acid analogs under evaluation as prostaglandin I2-preferring receptor antagonists was studied. The initial analog with unsubstituted phenyl groups was subject to a complex set of aromatic oxidative biotransformations. By introduction of one or two fluorines, these pathways were inhibited. All three analogs were metabolized to a wide variety of carboxylic acid conjugates. Among these were several conjugates formed via secondary metabolism and oxidation of acyl glutathione intermediates. Two of the structure classes, represented by the S-methyl-N-cysteinylglycine conjugate and the N-cysteinylglycine disulfide conjugates, have been described only rarely in the literature. The related S-oxide of the S-methyl-N-cysteinylglycine conjugate and the N,S-bis-acyl derivative of cysteinylglycine are here described for the first time as conjugate metabolites of car boxylic drugs.


Journal of Medicinal Chemistry | 2015

Novel Series of Dihydropyridinone P2X7 Receptor Antagonists

Francisco Javier Lopez-Tapia; Keith Adrian Murray Walker; Christine Brotherton-Pleiss; Joanie Caroon; Dov Nitzan; Lee Edwin Lowrie; Shelley K. Gleason; Shu-Hai Zhao; Jacob Berger; Debra Cockayne; Deborah Phippard; Rebecca T. Suttmann; William L. Fitch; David L. Bourdet; Pankaj D. Rege; Xiaojun Huang; Scott Broadbent; Charles Alois Dvorak; Jiang Zhu; Paul J. Wagner; Fernando Padilla; Brad Loe; Alam Jahangir; André Alker

Identification of singleton P2X7 inhibitor 1 from HTS gave a pharmacophore that eventually turned into potential clinical candidates 17 and 19. During development, a number of issues were successfully addressed, such as metabolic stability, plasma stability, GSH adduct formation, and aniline mutagenicity. Thus, careful modification of the molecule, such as conversion of the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper substitution at C-5″, and in some cases addition of fluorine atoms to the aniline ring allowed for the identification of a novel class of potent P2X7 inhibitors suitable for evaluating the role of P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders.


Tetrahedron Letters | 1999

N-methylanilines from benzylic azides

Francisco J. Lopez; Dov Nitzan

Benzylic azides are converted into N-methylanilines efficiently in the presence of a Bronsted or Lewis acid and Et3SiH. The combination of SnCl4Et3SiH and 4-n-butylbenzyl azide appears to form an aminodiazonium trichlorostannate(II), which undergoes the rearrangement to an iminium salt that is then reduced to N-methyl-4-n-butylaniline by Et3SiH.


Archive | 2002

Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists

Francisco Javier Lopez-Tapia; Dov Nitzan; Counde O'yang


Archive | 2004

Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

Terrence Joseph Connolly; Paul Francis Keitz; Eun Kyung Lee; Jim Li; Francisco Javier Lopez-Tapia; Patrick Finbar Mcgarry; Chris Richard Melville; Dov Nitzan; Counde O'yang; Fernando Padilla; Klaus Kurt Weinhardt


Archive | 2002

Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists

Francisco Javier Lopez-Tapia; Dov Nitzan; Counde O'yang


Heterocycles | 2002

Synthesis and biological evaluation of ketorolac analogs

Francisco J. Lopez; Mary-Frances Jett; Joseph M. Muchowski; Dov Nitzan; Counde O'yang


Archive | 2004

Arylamine-substituted quinazolinone compounds

Terrence Joseph Connolly; Paul Francis Keitz; Eun Kyung Lee; Jim Li; Francisco Javier Lopez-Tapia; Patrick Finbar Mcgarry; Chris Richard Melville; Dov Nitzan; Counde O'yang; Fernando Padilla; Klaus Kurt Weinhardt


Archive | 2009

Dihydropyridone ureas as p2x7 modulators

Christine E. Brotherton-Pleiss; Joan M. Caroon; Francisco Javier Lopez-Tapia; Dov Nitzan; Keith Adrian Murray Walker

Collaboration


Dive into the Dov Nitzan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge